title: Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.
abstract: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication seen most frequently in patients on intravenous bisphosphonates treatment for malignant diseases. High potency bisphosphonates are generally implicated and risk factors also include dental extractions. Prevention is of paramount importance. Management is controversial but there is little evidence basis and the consensus is to be conservative. Recent advances in this area are summarised in this concise review.
authors.affiliation: Valencia University, Valencia, Spain. bagan@uv.es
authors.forename: Jose
authors.initials: J
authors.lastname: Bagan
authors.forename: Crispian
authors.initials: C
authors.lastname: Scully
authors.forename: Vicente
authors.initials: V
authors.lastname: Sabater
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Jimenez
mesh_terms: D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000628:therapy; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates